{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:47:01Z","timestamp":1785804421943,"version":"3.56.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jss.2026.05.079","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:59:22Z","timestamp":1782849562000},"page":"609-614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The Price of Progress: Cost Considerations in Hepatocellular Carcinoma Clinical Trials"],"prefix":"10.1016","volume":"325","author":[{"given":"James L.","family":"Rogers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9506-3097","authenticated-orcid":false,"given":"Maro M.","family":"Doce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wali R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin I.","family":"Montenovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2026.05.079_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jss.2026.05.079_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jss.2026.05.079_bib3","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jss.2026.05.079_bib4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cgh.2017.07.024","article-title":"Healthcare costs related to treatment of hepatocellular carcinoma among veterans with cirrhosis in the United States","volume":"16","author":"Kaplan","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jss.2026.05.079_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40273-019-00839-9","article-title":"Economic implications of hepatocellular carcinoma surveillance and treatment: a guide for clinicians","volume":"38","author":"Likhitsup","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jss.2026.05.079_bib6","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl l","key":"10.1016\/j.jss.2026.05.079_bib7","article-title":"Lack of pre-planned financial outcomes evaluation in phase 3 cancer trials","volume":"39","author":"Noticewala","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2026.05.079_bib8","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.jval.2020.08.2095","article-title":"Economic evaluations in national Cancer Institute\u2013Sponsored network Cancer clinical trials","volume":"23","author":"Nghiem","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.jss.2026.05.079_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185198","article-title":"Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting","volume":"12","author":"Thein","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jss.2026.05.079_bib10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1524-4733.2005.00045.x","article-title":"Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report","volume":"8","author":"Ramsey","year":"2005","journal-title":"Value Health"},{"key":"10.1016\/j.jss.2026.05.079_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","article-title":"Cost-effectiveness analysis alongside clinical trials II\u2014An ISPOR Good Research Practices Task Force report","volume":"18","author":"Ramsey","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.jss.2026.05.079_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2025.104655","article-title":"Cost evaluation in head and neck cancer clinical trials: implications for high-value care","volume":"46","author":"Collins","year":"2025","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.jss.2026.05.079_bib13","article-title":"Cost analysis in thyroid cancer clinical trials: toward value-based oncology care","volume":"252","author":"Rogers","year":"2025","journal-title":"Am J Surg"},{"key":"10.1016\/j.jss.2026.05.079_bib14","article-title":"Cost-effectiveness of atezolizumab and bevacizumab in advanced hepatocellular carcinoma","volume":"19","author":"Patel","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2026.05.079_bib15","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study","volume":"15","author":"Liu","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.jss.2026.05.079_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11912-017-0599-0","article-title":"Cost-Effectiveness of stereotactic radiosurgery and stereotactic body radiation therapy: a critical review","volume":"19","author":"Lester-Coll","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jss.2026.05.079_bib17","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.28131","article-title":"Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer","volume":"119","author":"Shah","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jss.2026.05.079_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4846","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib for patients with unresectable or metastatic hepatocellular carcinoma","volume":"4","author":"Zhang","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002248042600377X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002248042600377X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:30:12Z","timestamp":1785803412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002248042600377X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":18,"alternative-id":["S002248042600377X"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2026.05.079","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Price of Progress: Cost Considerations in Hepatocellular Carcinoma Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2026.05.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}